The biopharmaceutical AbilityPharma, a member of CATALONIA.HEALTH, has published in BMC Cancer the final data of its phase 1/2 ENDOLUNG trial that evaluates the drug IBRILATAZAR (ABTL0812) in combination with chemotherapy for patients with advanced or recurrent endometrial cancer.  

The trial had the contribution of world opinion leaders from selected hospitals in Spain and France to assess the safety and efficacy of the drug IBRILATAZAR with chemotherapy. It was done in 51 patients with advanced or recurrent endometrial cancer in 9 leading cancer hospitals in both countries.  

This relevant publication is based on the innovative translational research done previously by AbilityPharma, published in Gynecologic Oncology. These advances further establish the leadership of the company in the development of oncological drugs through autophagy.  

"This publication is crucial in the study of new drugs and combinations with chemotherapy for advanced endometrial cancer and marks a significant achievement in AbilityPharma's mission to offer transformative treatments to cancer patients," says Dr. Carles Domènech, CEO and co-founder of AbilityPharma. 

More information 

Related news: 

• AbilityPharma closes a €7 million investment round for the drug ABTL0812 in phase 2b clinical trial in metastatic pancreatic cancer (14 March 2024)